Compare MESO & BL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | BL |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | Australia | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | N/A | 2016 |
| Metric | MESO | BL |
|---|---|---|
| Price | $15.06 | $35.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $57.23 |
| AVG Volume (30 Days) | 256.0K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $177,031,000.00 |
| Revenue This Year | $644.56 | $12.62 |
| Revenue Next Year | $38.70 | $10.90 |
| P/E Ratio | ★ N/A | $92.72 |
| Revenue Growth | N/A | ★ 43.78 |
| 52 Week Low | $9.61 | $31.75 |
| 52 Week High | $21.50 | $59.57 |
| Indicator | MESO | BL |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 35.36 |
| Support Level | $14.53 | $31.75 |
| Resistance Level | $17.42 | $58.86 |
| Average True Range (ATR) | 0.55 | 1.63 |
| MACD | -0.00 | 0.68 |
| Stochastic Oscillator | 41.82 | 55.38 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.